Decreased interleukin-10 serum levels in first-episode drug-naïve schizophrenia: Relationship to psychopathology

Schizophrenia Research

Volumn 156, Issue 1, 2014, Pages 9-14

  Xiu, Mei Hong ^a   Yang, Gui Gang ^a   Tan, Yun Long ^a   Chen, Da Chun ^a   Tan, Shu Ping ^a   Wang, Zhi Ren ^a   Yang, Fu De ^a   Okusaga, Olaoluwa ^b   Soares, Jair C ^b   Zhang, Xiang Yang ^a,b  

^a PEKING UNIVERSITY   (China)

^b University of Texas Harris County Psychiatric Center   (United States)

Author keywords

Cognition; Cytokines; Immune function; Interleukin 10; Psychopathology; Schizophrenia

Indexed keywords

INTERLEUKIN 10;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATIONAL STATUS; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SMOKING; ANALYSIS OF VARIANCE; BLOOD; COGNITION DISORDERS; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MENTAL DISEASE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; STATISTICS; YOUNG ADULT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOPATHOLOGY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84899896793     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.03.024     Document Type: Article

References (62)

1. Arimoto T., Choi D.Y., Lu X., Liu M., Nguyen X.V., Zheng N., Stewart C.A., Kim H.C., Bing G. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol. Aging 2007, 28(6):894-906.
2. Arosio B., Mastronardi L., Vergani C., Annoni G. Intereleukin-10 promoter polymorphism in mild cognitive impairment and in its clinical evolution. Int. J. Alzheimers Dis. 2010, 2010.
3. Asevedo E., Rizzo L.B., Gadelha A., Mansur R.B., Ota V.K., Berberian A.A., Scarpato B.S., Teixeira A.L., Bressan R.A., Brietzke E. Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiol. Behav. 2014, (Feb 25 pii: S0031-9384(14)00101-2 Epub ahead of print). 10.1016/j.physbeh.2014.02.032.
4. Barch D.M., Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn. Sci. 2012, 16(1):27-34.
5. Bocchio Chiavetto L., Boin F., Zanardini R., Popoli M., Michelato A., Bignotti S., Tura G.B., Gennarelli M. Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol. Psychiatry 2002, 51(6):480-484.
6. Cazzullo C.L., Scarone S., Grassi B., Vismara C., Trabattoni D., Clerici M. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22(6):947-957.
7. Chengappa K.N., Ganguli R., Yang Z.W., Shurin G., Brar J.S., Rabin R.S. Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol. Psychiatry 1995, 37:546-549.
8. Citrome L., Meng X., Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr. Res. 2011, 131(1-3):75-81.
9. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int. J. Neuropsychopharmacol. 2011, 14(7):997-1012.
10. Ding M., Song X., Zhao J., Gao J., Li X., Yang G., Wang X., Harrington A., Fan X., Lv L. Activation of Th17 cells in drug naïve, first episode schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 51:78-82.
11. Erbagci A.B., Herken H., Koyluoglu O., Yilmaz N., Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediat. Inflamm. 2001, 10(3):109-115.
12. Freudenreich O., Brockman M.A., Henderson D.C., Evins A.E., Fan X., Walsh J.P., Goff D.C. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res. 2010, 176(2-3):99-102.
13. Ganguli R., Brar J.S., Chengappa K.N., Yang Z.W., Nimgaonkar V.L., Rabin B.S. Autoimmunity in schizophrenia: a review of recent findings. Ann. Med. 1993, 25(5):489-496.
14. Goff D.C., Hill M., Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol. Biochem. Behav. 2011, 99(2):245-253.
15. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 2007, 78:1-39.
16. Hope S., Ueland T., Steen N.E., Dieset I., Lorentzen S., Berg A.O., Agartz I., Aukrust P., Andreassen O.A. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr. Res. 2013, 145(1-3):36-42.
17. Howard M., O'Garra A. Biological properties of interleukin 10. Immunol. Today 1992, 13(6):198-200.
18. Hwang Y., Kim J., Shin J.Y., Kim J.I., Seo J.S., Webster M.J., Lee D., Kim S. Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl. Psychiatry 2013, 3:e321.
19. Kaminska T., Wysocka A., Marmurowska-Michalowska H., Dubas-Slemp H., Kandefer-Szerszen M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch. Immunol. Ther. Exp. (Warsz) 2001, 49(6):439-445.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
21. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee H.J., Kim D.J., Leonard B.E. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(7):1129-1134.
22. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 2000, 157(5):683-694.
23. Kubistova A., Horacek J., Novak T. Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr. Danub. 2012, 24(Suppl. 1):S153-S156.
24. Kunz M., Cereser K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 2011, 33(3):268-274.
25. Ledeboer A., Breve J.J., Wierinckx A., van der Jagt S., Bristow A.F., Leysen J.E., Tilders F.J., Van Dam A.M. Expression and regulation of interleukin-10 and interleukin-10 receptor in rat astroglial and microglial cells. Eur. J. Neurosci. 2002, 16(7):1175-1185.
26. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpe S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998, 32(1):9-15.
27. Maes M. Cytokines in schizophrenia. Biol. Psychiatry 1997, 42(4):308-309.
28. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995, 29(2):141-152.
29. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Altamura C.A. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 2002, 54(3):281-291.
30. Marchant A., Deviere J., Byl B., De Groote D., Vincent J.L., Goldman M. Interleukin-10 production during septicaemia. Lancet 1994, 343(8899):707-708.
31. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
32. Miller B.J., Gassama B., Sebastian D., Buckley P., Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2013, 73(10):993-999.
33. Molina-Holgado F., Grencis R., Rothwell N.J. Actions of exogenous and endogenous IL-10 on glial responses to bacterial LPS/cytokines. Glia 2001, 33(2):97-106.
34. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
35. Muller N., Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22(1):1-33.
36. Muller N., Hofschuster E., Ackenheil M., Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr. Scand. 1993, 87:66-71.
37. Na K.S., Jung H.Y., Kim Y.K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48:277-286.
38. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 1996, 20(3):269-273.
39. Nie K., Zhang Y., Gan R., Wang L., Zhao J., Huang Z., Tang H. Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson's disease with cognitive impairment in the Han Chinese population. Neurosci. Lett. 2013, 541:111-115.
40. O'Brien S.M., Scully P., Dinan T.G. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res. 2008, 160(3):256-262.
41. Pedrini M., Massuda R., Fries G.R., de Bittencourt Pasquali M.A., Schnorr C.E., Moreira J.C., Teixeira A.L., Lobato M.I., Walz J.C., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J. Psychiatr. Res. 2012, 46(6):819-824.
42. Pickering M., O'Connor J.J. Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog. Brain Res. 2007, 163:339-354.
43. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
44. Rapaport M.H., Stein M.B. Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia. Anxiety 1994, 1(2):50-53.
45. Rapaport M.H., McAllister C.G., Pickar D., Tamarkin L., Kirch D.G., Paul S.M. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr. Res. 1997, 25(2):123-129.
46. Rodriguez-Jimenez R., Bagney A., Mezquita L., Martinez-Gras I., Sanchez-Morla E.M., Mesa N., Ibanez M.I., Diez-Martin J., Jimenez-Arriero M.A., Lobo A., Santos J.L., Palomo T. Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia. Schizophr. Res. 2013, 143(1):77-83.
47. Romagnani S. T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol. 2000, 85(1):9-18. (quiz 18, 21).
48. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., Kirchner H. Production of cytokines in acute schizophrenic psychosis. Biol. Psychiatry 1996, 40(12):1294-1297.
49. Sawada M., Suzumura A., Hosoya H., Marunouchi T., Nagatsu T. Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J. Neurochem. 1999, 72(4):1466-1471.
50. Schwarz M.J., Muller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med. Hypotheses 2001, 56(4):483-486.
51. Severance E.G., Gressitt K.L., Stallings C.R., Origoni A.E., Khushalani S., Leweke F.M., Dickerson F.B., Yolken R.H. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr. Res. 2013, 148(1-3):130-137.
52. Smith R.S. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med. Hypotheses 1992, 39(3):248-257.
53. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses 1995, 45(2):135-141.
54. Strle K., Zhou J.H., Shen W.H., Broussard S.R., Johnson R.W., Freund G.G., Dantzer R., Kelley K.W. Interleukin-10 in the brain. Crit. Rev. Immunol. 2001, 21(5):427-449.
55. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., Zhang X.Y. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci. Lett. 2005, 382(1-2):27-32.
56. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr. Res. 2012, 137(1-3):246-250.
57. Weinberger D.R., Berman K.F. Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr. Bull. 1988, 14(2):157-168.
58. Westermann J., Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system?. Immunol. Today 1990, 11(11):406-410.
59. Woiciechowsky C., Schöning B., Lanksch W.R., Volk H.D., Döcke W.D. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J. Mol. Med. 1999, 77(11):769-780.
60. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 2011, 25(2):181-213.
61. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res. 2002, 57(2-3):247-258.
62. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Haile C.N., Kosten T.A., Kosten T.R. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J. Psychiatr. Res. 2007, 41(12):997-1004.